Daniel Fady, Loriot Marie-Anne, Seksik Philippe, Cosnes Jacques, Gornet Jean-Marc, Lémann Marc, Fein Francine, Vernier-Massouille Gwenola, De Vos Martine, Boureille Arnaud, Treton Xavier, Flourié Bernard, Roblin Xavier, Louis Edouard, Zerbib Frank, Beaune Philippe, Marteau Philippe
Department of Gastroenterology, Assistance Publique des Hôpitaux de Paris (AP-HP), Hôpital Européen Georges Pompidou, Paris, France.
Inflamm Bowel Dis. 2007 Jan;13(1):19-23. doi: 10.1002/ibd.20046.
Cyclosporine A (CsA) is inconstantly effective in inducing remission in acute attacks of ulcerative colitis (UC) not responding to steroids. This study aimed to establish whether multidrug resistance gene (MDR)1 polymorphisms would be associated with CsA failure.
The distribution of the different genotypes of single nucleotide polymorphisms (SNP) G2677T/A and C3435T of MDR1 exons 21 and 26, respectively, was studied in 154 patients (mean age, 44 yr) who had received CsA to treat severe attacks of steroid resistant UC in 11 centers in France and Belgium. Patients were classified as CsA failure (n = 50) when they needed colectomy within 30 days after CsA initiation. The SNPs were detected by use of a 5' nuclease allelic discrimination assay.
There was a significant association between the G2677T/A polymorphism distribution (exon 21) and the risk for CsA failure (P = 0.0001). The TT genotype of exon 21 was significantly associated with the risk compared with the two other genotypes (odds ratio, 3.77; 95% confidence interval, 1.42-9.97, P = 0.007). There was no significant association between the genotype C3435T distribution (exon 26) and the risk of CsA failure (P = 0.23).
The TT genotype of exon 21 MDR1 polymorphisms is associated with a higher risk of CsA failure in patients with steroid resistant UC. Further studies should be performed to establish whether other treatments could be more efficient to avoid surgery in this subset of patients.
环孢素A(CsA)在诱导对类固醇治疗无反应的溃疡性结肠炎(UC)急性发作缓解方面疗效不一。本研究旨在确定多药耐药基因(MDR)1多态性是否与CsA治疗失败相关。
在法国和比利时的11个中心,对154例(平均年龄44岁)接受CsA治疗类固醇抵抗性UC严重发作的患者,研究了MDR1外显子21和26的单核苷酸多态性(SNP)G2677T/A和C3435T不同基因型的分布情况。当患者在CsA开始使用后30天内需要进行结肠切除术时,被归类为CsA治疗失败(n = 50)。通过5'核酸酶等位基因鉴别分析检测SNP。
G2677T/A多态性分布(外显子21)与CsA治疗失败风险之间存在显著关联(P = 0.0001)。与其他两种基因型相比,外显子21的TT基因型与该风险显著相关(优势比,3.77;95%置信区间,1.42 - 9.97,P = 0.007)。C3435T基因型分布(外显子26)与CsA治疗失败风险之间无显著关联(P = 0.23)。
MDR1外显子21多态性的TT基因型与类固醇抵抗性UC患者CsA治疗失败风险较高相关。应进一步开展研究,以确定在这部分患者中是否有其他治疗方法能更有效地避免手术。